healthcare-reports

[healthcare-reports]

Global Non-invasive prenatal testing (NIPT) Market Share, Growth and Trend Analysis, 2015 to 2025

7 January 2019, the global non-invasive prenatal testing (NIPT) market is estimated to witness significant growth in the coming years due to growing popularity of non-invasive procedures. Improvement in reimbursement policies and introduction of advanced NIPT products are likely to support market growth. Rising awareness regarding these tests across the globe is also poised to create lucrative opportunities in the future. In present days, obstetricians are extensively suggesting these tests for early diagnostic screening in the first trimester of pregnancy.

Prenatal testing helps in determining the possibility of fetal abnormality. Development of these tests in a noninvasive form helps avoid expensive and risky invasive procedures such as chorionic villus sampling (CVS) and amniocentesis. Improvements by payers in coverage related to average risk pregnancy tests are anticipated to fuel the adoption of amniocentesis tests and Down’s syndrome treatment. This, in turn, is estimated to augment adoption rate of non-invasive prenatal aids.

Growing maternal age is projected to unfold ample growth opportunities in the market. Advancing maternal age is responsible for several health complications such as high blood pressure, reduced fertility, risk of miscarriage, and maternal death. It also increases the risk of chromosomal abnormalities in babies. Possible abnormalities in babies may include poor muscle tone, breathing complaints, heart related problems, and others. Increasing consciousness regarding prevention and screening of chromosomal anomalies can boost market growth in the coming years.

Browse Details of Report @ https://www.hexaresearch.com/research-report/non-invasive-prenatal-testing-nipt-market

However, presence of strict regulatory framework regarding approval of medical devices can hinder the growth of the market. Lengthy approval procedures delay innovation and development of devices. In addition, lack of skilled professionals is also expected to restrain the growth of the non-invasive prenatal testing market.

Various techniques involved in NIPT tests include fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, biochemical screening tests, and ultrasound detection. Cell-free DNA in maternal plasma tests are anticipated to witness an upswing in their demand in the coming years. This can be attributed to growing requirement for cf-DNA-based techniques in NIPT testing. In addition, increasing government efforts for providing prenatal services are likely to stir up the demand for these tests.

North America is considered as one of the attractive markets in the global arena. High government spending for research and development (R&D) activities and development of whole genome sequencing as a result of availability of technologically advanced and presence of established healthcare research framework have been providing an upthrust to the regional market.

On the other hand, Asia Pacific is poised to exhibit noteworthy growth in the coming years. Rising average maternal age, improving healthcare facilities, rising disposable income, and high prevalence of chromosomal abnormalities are some of the primary growth stimulants for the regional market. Advancing maternal age and high-risk pregnancies in China are projected to create lucrative growth opportunities for the regional market in near future.

Countries such as Japan and China are sights of high growth rates in the region. Additionally, improvement in healthcare facilities along with growing exposure for clinical research in India and Australia are also projected to support the growth of the market in APAC in the coming years.

Some of the key players operating in the global non-invasive prenatal testing market are Sequenom Inc.; PerkinElmer, Inc.; Agilent Technologies, Inc.; Pacific Biosciences of California, Inc.; and Quest Diagnostics. Various laboratories and companies are collaborating with test provides for providing latest products and services to patients. This is anticipated to work in favor of the market.

In addition, public health agencies in major economies in the world are providing these tests directly, which is expected to bode well for the market. Companies are concentrating on development and launch of advanced tests. For instance, LifeCell, stem cell bank from India, introduced 'Pentastic', an ultrasound and biochemistry-based blood test. This test has to be carried out in the first trimester of pregnancy between 11 to 13 weeks. The screening can be performed to detect abnormalities related to genes and structural malformations in fetus. The test is also helpful to examine serious high blood pressure in pregnancy.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

[healthcare-reports]

Pharmerging Market Size, Growth, Competitive Strategies and Forecasts, 2015 to 2025

24 December 2018, The Global Pharmerging Market is anticipated to witness steady CAGR over the forecast period. Factors such as rising population due to low infant mortality rates and high focus on developing innovative drugs are expected to boost the growth. Among 17 emerging countries; China, India, and Russia are projected to hold a major market share in near future.

Patent expirations and availability of low cost generic drugs are anticipated to slow down sales in matured markets such as U.S, Europe, Japan, Canada, and U.K. As a result, major players are expected to bring in new products to maintain and even expand their industry share. This factor is likely to drive the pharmerging market in the forthcoming years. Launch of innovative products for diseases such as lupus, diabetes, arrhythmia, melanoma, prostate cancer, and osteoporosis among others may positively influence expansion in near future.

Macroeconomic factors such as greater awareness about drugs in semi-urban and rural markets and epidemiological changes are anticipated to propel growth of the market for pharmerging over the forecast period. High prevalence of age-related disorders and rapid development in private hospital industry are also expected to bode well for expansion. Increased healthcare expenditure by governments is expected to further drive growth.

Emerging markets are likely to focus more on development of low cost generic drugs. This factor is anticipated to restrain growth of pharmerging in these regions. Changes in regulatory policies are likely to curb the growth as they have long-term impacts on pricing and medicine usage. Price sensitivity is another challenge likely to be faced by major companies. Regulatory norms such as the Affordable Care Act in U.S. and Japan’s price cut system are projected to rebalance spending priorities for markets.

Browse Details of Report @ https://www.hexaresearch.com/research-report/pharmerging-market

Possibility of including major drugs under Drug Price Control Order (DPCO) may affect the retail and wholesale margins earned by chemists. Lower margins are further expected to lead to reduced production rates. Some of the major pharmaceutical companies which have experienced a negative growth rate due to DPCO include Sanofi-Aventis, Lupin, Zydus Cadila, etc. this factor is expected to negatively influence growth pharmerging.

On the basis of pharma growth requirements, pharmerging countries are categorized into tier-I, tier-II, and tier-III. Tier-I includes China while Tier-II includes India, Brazil, and Russia. Tier-III includes Turkey, Indonesia, Thailand, Vietnam, Egypt, South Africa and Mexico. China is a very complex market and is expected to focus on sophisticated operating models. Shrinking prices, complex distribution system, different commercial models in different provinces, and regulations favoring domestic manufacturers are the primary challenges faced by new entrants in China.

Indian market is expected to be highly fragmented and competitive. Strategic planning coupled with new product launches can help major pharmaceutical companies to be successful in this region. Adaption of local trends and strategic market entry can help new entrants. Russia is likely to be very volatile, due to price control system for essential drugs. Also, policies such as substitution of imported drugs with locally manufactured equivalents may pose a challenge to major players.

The market in Brazil is anticipated to be commoditized in retail segment as unmet medical needs are mostly satisfied by nonretail drugs. Establishment of CITEC/CONITEC is likely to act as a barrier for product inclusions in funding programs. Innovation is focused on niche private segments as demand for expenditure on complex therapies is usually avoided.

Major players operating in the market for pharmerging are AstraZeneca, Sanofi, Merck, Pfizer, GlaxoSmithKline, Novartis, Abbott Laboratories, CSL Behring, Johnson & Johnson, Sun Pharmaceutical, Aspen, Teva Pharmaceutical, Bayer, Valeant Pharmaceutical, Biogen, Baxter, STADA, Mylan, Takeda Pharma, Alexion Pharmaceuticals, and Endo Health Pharmaceuticals. The market is highly fragmented due to the presence of small and medium businesses. Product launches, mergers and acquisitions, and innovations are anticipated to define competition among top players. Majority of companies focus on merger and acquisitions to expand market presence and increase profits.

Major pharmaceutical companies are expected to deal with some uncertainties in terms of regulation and pricing policies laid down to ensure a profitability. Anticipation and analysis of compliance risks and implementation of suitable market entry strategies are some of the popular business strategies.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

Visceral Pain Market Size, Shares, Growth and Trend Analysis, 2014 to 2024

11 December 2018, the global Visceral Pain Market is expected to reach USD 14.22 billion by 2024, driven by the increasing geriatric population globally. Increasing prevalence of visceral pain and rising awareness regarding the same is projected to drive market growth over the forecast period.

In 2016, North America held the majority of share in global visceral pain market owing to the increasing healthcare expenditure. Additionally, the high prevalence of Crohn’s and irritable bowel is expected to propel the growth of the market over the projected period.

Asia Pacific is expected to be the fastest growing region with the CAGR of 6.2%. The increase in the healthcare infrastructure and presence of a large pool of patients is projected to drive the demand for the visceral pain industry during the forecast period.

Analgesic segment dominated the market for the visceral pain with the market share of 60.4%. The major share of the analgesic segment is attributed to the increasing penetration of generic drug. Furthermore, rising healthcare expenditure and an increasing use of opioids for the chronic pain are the key factors attributing to its share.

Browse Details of Report @ https://www.hexaresearch.com/research-report/high-heat-foam-market

In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4% of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore, increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.

Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their products to patients affected by visceral pain. The growth of the geriatric population is expected to help in augmenting the profits of these companies over the next few years.

Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry during the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to propel the market growth.

Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and region:

Segmentation by therapeutics, 2014 - 2024 (USD Million) • Analgesics     • Narcotics     • NSAID • Pain modifiers     • Tricyclic Antidepressants     • Tricyclic Anticonvulsant • Others

Segmentation by indications, 2014 - 2024 (USD Million) • Interstitial cystitis • Crohn’s • Irritable bowel • Chronic prostatitis

Segmentation by region, 2014 - 2024 (USD Million) • North America • Europe • Asia Pacific • Rest of the World (RoW)

Key players analyzed • Pfizer Inc. • Allergan  • Johnson & Johnson • Bayer AG • Takeda Pharmaceutical Company Limited • Mallinkrodt Pharmaceuticals • AbbVie Inc. • AstraZeneca

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

[healthcare-reports]

Medical Morphine Market Size, Share, Growth, Trends and Forecast, 2014 to 2024

29 November 2018, the global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine.

Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.

Hexa Research has segmented the global medical morphine market based on Route of Administration, Indication and region:

Segmentation by Route of Administration, 2014 - 2024 (USD Million) • Oral  • Injectables • Others

Segmentation by Indication, 2014 - 2024 (USD Million) • Cancer • Arthritis • Others

Segmentation by Region, 2014 - 2024 (USD Million) • North America     • U.S. • Europe     • Germany • Asia Pacific     • China     • India • Rest of the World

Key players analyzed • Mallinckrodt Pharmaceuticals • Alcaliber S.A. • Purdue Pharma L.P. • Pfizer Inc. • Johnson Matthey Fine Chemicals • Sun Pharmaceutical Industries Ltd. • Verve Health Care Ltd. • Taj Pharmaceuticals Limited • NORTHEAST PHARM • MANUS AKTTEVA BIOPHARMA LLP

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

Herbal Medicine Market Size, Share, Growth and Industry Research Report, 2014 to 2024

29 November 2018, the global Herbal Medicine Market is expected to reach USD 117.02 billion by 2024, driven by rising popularity of herbal therapeutics compared to conventional drugs. The market for herbal medicines and remedies is anticipated to record profitable growth due to their cost-effectiveness as compared to allopathic ones.

In 2016, Europe was the largest market for traditional medicines, contributing to 40.8% of the share and is expected to retain its leadership during the forecast period due to shifting from conventional drugs to herbal products. Fewer side effects and low toxicity compared to allopathy products are expected to provide a competitive advantage over other medicines in the market. Additionally, ready acceptance of herbal products owing to its benefits is the key factor for market growth and is expected to play a significant role in future.

Increased preference of complementary and alternative medicine (CAM) among others has resulted in the growth of herbal medicines in Asia Pacific. Asia Pacific is expected to record the fastest CAGR of 6.8% over the forecast period. Furthermore, Europe is anticipated to generate maximum revenue over the forecast period due to increasing awareness created by various associations such as Association for Natural Medicine in Europe (AIME).

Browse Details of Report @ https://www.hexaresearch.com/research-report/global-herbal-medicine-market

Concerning product segment, tablets & capsules are expected to witness the fastest growth owing to increasing acceptance of tablets over extracts and powders. Furthermore, properties such as high dose accuracy essential for optimum therapeutic effect will, in turn, promote the herbalism market growth. The extracts segment is expected to grow at a lucrative rate as they show an immediate therapeutic effect on administration.

For instance, in geriatric patients, extracts and other liquid dosage forms are preferred for administration as tablets show delayed therapeutic effect. Furthermore, extracts provide high potency as they possess only the active ingredients and no fillers which are present in tablets & capsules.

The rigorous focus on developing better extraction and purification techniques by herbal medicine manufacturers is expected to fuel the market. Furthermore, respective governments are also introducing several strategies to promote the uptake of herbal medicine market. For instance, in July 2017, the Chinese Ministry of Science and Technology invested USD 12.5 million for development of herbal treatments for the treatment of cancer and HIV/AIDS.

Hexa Research has segmented the global herbal medicine market based on Product, Indication, and region:

Segmentation by Product, 2014 - 2024 (USD Billion) • Tablets & Capsules • Powders • Extracts • Others

Segmentation by Indication, 2014 - 2024 (USD Billion) • Digestive Disorders • Respiratory Disorders • Blood Disorders • Others

Segmentation by Region, 2014 - 2024 (USD Billion) • North America     • U.S. • Europe     • Germany • Asia Pacific     • China     • India • Central & South America • Middle East and Africa

Key Players Analyzed • TSUMURA & CO. • Dr. Willmar Schwabe India Pvt. Ltd. • Blackmores • NATURE'S ANSWER • Arkopharma • Arizona Natural Products • Herbal Africa • Bio Botanica, Inc. • Sidomuncul • Nature Herbs

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

Somatostatin Analogs Market Size, Share, Growth, Trends and Forecast, 2014 to 2024

28 November 2018, The Global Somatostatin Analogs Market size to reach USD 3.1 billion by 2024, owing to the rise in the incidence rate of acromegaly and neuroendocrine tumor over the forecast period. Rising awareness, training and education by Pituitary Association of Australia and UK & Ireland Neuroendocrine Tumor Society is expected to have positive impact on the market growth in the coming years.

The octreotide type analog brand Sandostatin accounted for more than 67% of the market share in 2016. The demand for octreotide is expected to show stagnant growth over the forecast period. Owing to the patent expiration of the drug Sandostatin LAR in 2014 in U.S., which was being marketed by Novartis in North America, Europe and many other countries across the globe. Rising popularity of Lanreotide brand Somatuline in the U.S. and Europe is expected to fuel the market growth. Increasing penetration and popularity of the drug in the market coupled with the rise in the use of Somatuline lanreotide for carcinoid syndrome and other related disorder is expected to provide lucrative growth opportunity for the somatostatin analogs in near future.

Browse Details of Report @ https://www.hexaresearch.com/research-report/somatostatin-analogs-market

Lanreotide is a drug used in management and treatment of acromegaly. It is also administered in the treatment of symptoms caused by carcinoid syndrome. The molecule is long acting somatostatin analog similar to octreotide. The sequence for lanreotide is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. The drug is marketed under the brand name Somatuline and is manufactured by Ipsen.

Neuroendocrine tumor (NET) segment held more than 50% of the market share in 2016. Increasing incidence rate of neuroendocrine tumors and associated diseases such as carcinoid tumors is the key factor driving the growth of the market during the forecast period.

North America held more than 45% of market share in 2016. Increasing incidence of acromegaly and neuroendocrine tumor (NET) coupled with the rise in awareness and accuracy of disease diagnosis in developed economies is building a positive outlook for the acceptance of somatostatin analogs. Presence of favorable reimbursement policies, rise in the use of somatostatin analogs for treatment and, growing research and development activities in the North America is expected to have positive impact on market growth over the forecast period.

Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to the rise in the research and development activities in the medical field and the launch of innovative drug formulations are the main factor driving the growth of somatostatin analogs market over the forecast period.

The global somatostatin analogs industry is consolidated in nature with Novartis AG and IPSEN dominating market. Companies are adopting new strategies for increasing their R&D activities and introducing new product such as signifor and signifor LAR (Pasireotide) which are gaining momentum in U.S. and European market. Competetiors are also entering into new and potential markets where they can expect the product growth in the near future. For instance, Sun Pharma Advanced Research Company Ltd., had launch somatostatin analogs product for the treatment of acromegaly in India.

Hexa Research has segmented the global somatostatin analogs market report based on type, indication and region:

Segmentation by type, 2014 - 2024     • Octreotide     • Lanreotide     • Pasireotide

Segmentation by indication, 2014 - 2024     • Acromegaly     • Neuroendocrine Tumor (NET)     • Others

Segmentation by region, 2014 - 2024     • North America         • U.S.     • Europe         • Germany         • UK     • Asia Pacific         • China         • Japan     • Rest of the World (RoW)

Key players analyzed:     • Novartis AG     • Peptron     • Chiasma, Inc.     • Ipsen Biopharmaceuticals, Inc.     • Sun Pharma Advanced Research Company Ltd.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

Oligonucleotide Testing Market Size, Share, Growth and Trend Analysis, 2014 to 2024

28 November 2018, the global Oligonucleotide Testing Market to reach USD 1,746.52 million by 2024, owing to the increasing research and development activities in the field of oligonucleotide. For instance, nowadays, multifunctional oligonucleotide based aptamer molecules are widely studied biomedical class among scientists across the globe. Due to its unique chemistry and potential advantages compared to currently available drugs (i.e. antibodies), aptamer became one of the most budding market for the future period.

With the rising concept of oligonucleotide as diagnostic, research and therapeutic agent, it is noticed that companies investigating the potential of oligonucleotide is going up. Number of small companies or start-ups entering the market is continuously increasing due to its potential advantages. Over the past few years, there has been explosive growth in number of research article published in the area of oligonucleotide and its products.

Browse Details of Report @ https://www.hexaresearch.com/research-report/oligonucleotide-testing-market

According to the open access journal Multidisciplinary Digital Publishing Institute (MDPI AG), in 1995, there were not more than 200 research articles on aptamers. Compare to this, now it is around 1800 research literatures published by scientist on aptamer assays or therapeutics. This number indicates that companies focusing on the oligonucleotide drugs is rising every year. This fact would in turn cause a surge in demand for oligonucleotide testing services, augmenting growth. However, strict regulatory framework is anticipated to hamper the market expansion to some extent.

Types segment is categorized into Instrument, Software, and Services. Among which, instrument segment captured the largest share of the total market. Introduction of technological advanced chromatographic columns coupled with increasing demand for oligonucleotide synthesis drive the segment growth. Instrument segment is further divided into liquid chromatography, mass chromatography and capillary electrophoresis. In terms of application, the market is segmented as research and commercial. Research segment capture the largest share owing to the strong product pipeline.

In 2016, North America dominated the market contributing a share of more than 40% in the revenue generated worldwide. The primary reason being the high growth of this region, particularly in the U.S. is the rising research and development activities on oligonucleotides. Asia pacific region was estimated to be the fastest growing region in the global market and is anticipated to grow at a CAGR of about 10.8% by 2024. The growing need for effective therapeutics, rising awareness level, coupled with the favorable government initiatives are expected to drive growth in this region.

Currently there are very less approved oligonucleotide drugs namely fomivirsen (Vitravene), pegaptanib (Macugen), and mipomersen (Kynamro). Of which mipomersen and fomivirsen acti through RNase H mediated cleavage of targeted RNA. These drugs were developed by Ionis Pharmaceuticals. As the number of drugs available in the market are less, the oligonucleotide pipeline is strong and is expected to show positive response over the projection period.

Technological advances in development of oligonucleotide products has been one of the major market driver. Oligonucleotide synthesis has undergone tremendous changes which has resulted in rapid synthesis and cost-effective techniques of oligomer synthesis. Improvement of synthesis methods which include high throughput synthesizers, better coupling reagents and new sets of protective amino groups has drastically changed the nucleotide synthesis chemistry. With rapid development in oligonucleotide synthesis, the testing market is also expected to show lucrative growth. The major players are focusing on quality, service and innovation and adopting strategies such as product portfolio expansion, capacity expansions, and development of new facilities to gain market share.

Hexa Research has segmented the global personal protective equipment market report based on product type, application and region:

Segmentation by Type, 2014 - 2024     • Instrument         • Liquid Chromatography         • Mass Chromatography         • Capillary Electrophoresis     • Software     • Service

Segmentation by application, 2014 - 2024     • Research     • Commercial

Segmentation by region, 2014 - 2024     • North America         • U.S.     • Europe         • Germany         • UK     • Asia Pacific         • China         • India     • Rest of the world (RoW)

Key players analyzed:     • Thermo Fisher Scientific Inc.     • Merck KGaA      • Integrated DNA Technologies, Inc.     • Agilent Technologies     • Bruker

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

U.S. Wound Dressing Market Overview, Trends and Industry Statistics Report, 2013 to 2024

16 November 2018, The US Wound Dressing Market size is expected to reach USD 4.25 billion by 2024. Growing aging population and cases of diabetes and obesity are the major factors driving the market. Furthermore, increasing incidence of pressure ulcers in bedridden, wheelchair-bound, and/or physically impaired patients is expected to fuel the demand for wound care over the forecast period. For instance, annually, 2.5 million individuals suffer from pressure ulcer in U.S. and around USD 9.1 billion to USD 11.6 billion are spent for its treatment.

Moreover, growing cases of surgical procedures due to high incidence of wound infections and diabetic foot are expected to boost the demand for wound dressing. This has also increased the preference for advanced wound care products over simple dressing. Advanced dressing offers rapid healing, reasonable cost, with minimal inconvenience to the patient. However, owing to the demand for low cost dressing, traditional methods are being used to some extent. This may have a negative impact on the market development over the forecast period.

However, availability of various insurance schemes in U.S. for affordable medical care over long term, coupled with rise in consumer disposable income, is encouraging people to opt for advanced healthcare. This is anticipated to contribute to market expansion over the years to come.

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-wound-dressing-market

The advanced dressing technique is the fastest-growing segment expanding at a CAGR of 4.4% over the forecast period. It also held the dominant market share of USD 1.8 billion in 2017. It is expected to reach USD 2.6 billion by 2024. Advanced dressings includes moist, antimicrobial, and active dressings. Factors such as rapid healing and minimal patient inconvenience are anticipated impel this growth over the forecast period.

Chronic and non-healing wounds are best treated with advanced wound dressing products. Limitations of traditional wound care have propelled the growth of the segment. Advanced moist wound care is recommended for chronic wounds like pressure and diabetic ulcers, burn injuries, and other slow-healing wounds. Advanced foam technique is essential to prevent and heal the exudation of burn injuries. All these factors are projected to propel the growth of the U.S. wound dressing market during the forecast period.

Advanced alginate dressing is recommended in highly exuding wounds, as it forms a gel around the wound bed and helps in keeping them dry and clean. Advanced alginate dressing have gel-forming ability and they also help reduce the pain. As a result, they are widely used for the treatment for bleeding wounds. Advanced films provide healing to semi-dry and dry wounds. Advanced hydrocolloid dressing helps protect the wound internally, as well as externally. Increasing number of surgeries is expected to fuel the growth of hydrogel dressings. All these factors are expected to propel the growth of the wound dressing market over the forecast period.

Antimicrobial dressings are easy to use, accessible without prescription, and less risk of resistant. Silver and non-silver are the two types of this dressings. Silver shows broad spectrum antibacterial activity and minimal toxicity towards host cells. The non-sliver wound dressing may have single or combination of various ingredients, such as iodine, chlorhexidine, Polyhexamethylbuguanide (PHMB), honey, acetic acid, and potassium permanganate. This type of dressing is used for faster healing process and for reducing the pain. Active wound dressings are administered for the repair and healing through bioactive and skin-substitute compounds. They are highly beneficial in healing chronic moist wounds.

Hexa Research has segmented the U.S. wound dressing market report based on product:-

Segmentation by Product Type, 2013 - 2024     • Traditional     • Advanced         • Moist             • Foam             • Alginate             • Films             • Hydrocolloids             • Hydrogel         • Antimicrobial             • Silver             • Non-silver         • Active             • Biomaterials             • Skin-substitute

Key Players Analyzed     • 3M Healthcare     • Coloplast     • Medline Industries     • HARTMANN.     • BSN Medical     • Medtronic Plc     • Smith & Nephew     • ConvaTec     • Derma Sciences     • Systagenix

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

[healthcare-reports]

Hypodermic Needles Market Size, Share, Growth and Trend Analysis, 2014 to 2024

29 October 2018, the global Hypodermic Needle Market to reach USD 4,238.9 billion by 2024. Implementation of stringent legislation to reduce needlestick injury and increasing awareness related to safety needles among the healthcare provider is expected to drive the hypodermic needle market over the forecast period. Furthermore, increasing awareness of the regular immunizations coupled with increasing preference for regular health check-ups will further escalate the demand for hypodermic needles over the forecast period.

Moreover, rising geriatric population, increasing prevalence of diabetes, improving healthcare hygienic sample withdrawal practices in emerging economies such India, China, and Brazil is projected to propel the demand for hypodermic needle over the forecast period. However, the high cost of automated safety needles and the introduction of needleless delivery mechanisms might restrain the market growth in the forecast period.

Worldwide, needlestick injuries are the primary concern for healthcare providers. In the U.S., every year, approximately, 8 to 10 lac needlestick injuries occur to healthcare workers, and about 1000 of them get contacted with infectious diseases, and 500 to 600 die each year due to these types of injuries. The cost of needlestick injury follow-up in the U.S. per incident is approximately USD 3,000, and around USD 3 billion is spent annually in the U.S. on needlestick injuries. Hence, the increasing occurrence of these type of injuries results in the development of improved and effective safety needles.

Browse Details of Report @ https://www.hexaresearch.com/research-report/hypodermic-needles-market

Safety engineered devices (SEDs) are categorized into passive and active devices. Passive needles are highly preferred over conventional needles owing to its advantages such as user-friendliness and others. Also, with the implementation of the regulations promoting the use of safety hypodermic needles will further enhance the acceptance of these needles over the forecast period. For instance, World Health Organization (WHO) encourages injection safety worldwide through the Safe Injection Global Network (SIGN).

Exposure to needlestick injuries may cause severe blood-borne diseases such as HIV and Hepatitis. Owing to the increasing occurrence of needlestick injuries, healthcare providers are shifting towards the use of safety hypodermic needles. Furthermore, manufacturers are focusing on developing needles and syringes safety-engineered mechanisms to avoid any injuries. For instance, BD has developed SafetyGlide, Vacutainer Eclipse blood collection needle, and VanishPoint blood collection safety needle. Hence, increasing focus on the development of advanced engineered mechanisms about the needles performance and efficiency will further drive the growth.

Hexa Research has segmented the global hypodermic needle market based on type, end-use and region:

Segmentation by product type, 2014 - 2024 (USD Million)

• Safety Needle

• Non-safety Needle

Segmentation by end-user, 2014 - 2024 (USD Million)

• Hospitals & Clinic

• Diagnostic Lab

• Homecare

Segmentation by region, 2014 - 2024 (USD Million)

• North America

   • U.S.

• Europe

   • Germany

• Asia Pacific

   • Japan

   • China

   • India

• Central & South America

   • Brazil

• Middle East & Africa

Key players analyzed:

• Becton, Dickinson, and Company

• Medtronic

• Retractable Technologies

• Terumo Medical Corporation

• Smiths Medical

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

[healthcare-reports]

Type 1 Diabetes (T1D) Market Analysis, Growth Opportunities and Challenges, 2014 to 2024

The global Type 1 Diabetes Market is expected to reach USD 25.52 billion by 2024. A significant increase in the prevalence of type 1 diabetes coupled with Rigorous research & development activities to introduce novel formulations drives the T1D market growth.

Sedentary lifestyles, unhealthy diet habits coupled with rising obesity rates will further enhance the uptake of various types of insulin for the treatment of this disorder. Though this type of diabetes is rare still the number of cases is increasing by 3% every year according to the data enumerated by the International Diabetes Federation (IDF).

Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. This affects the respective countries and their national healthcare systems. For instance, the expenditure on diabetes management accounts for around 5% to 20% of the total healthcare spending.

Browse Details of Report @ https://www.hexaresearch.com/research-report/type-1-diabetes-t1d-market

Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the excess release of glucose in blood cells. The market penetration of long-acting insulin products is higher as compared to other two types, however, during the forecast period, the uptake and acceptance of rapid and premix analogs are anticipated to increase. The reason being the quick action and optimum performance of these two over long-acting insulin.

The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total market share. The reason being extensive product offerings and continuous research and development activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies. Also, high probability of launch of several biosimilars by new entrants, major players might face competition during the forecast period.

To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are continuously investing in the development of the improved versions of insulin products. For instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market.

Hexa Research has segmented the global type 1 diabetes (T1D) market based on insulin analog, and region:

Segmentation by insulin analog, 2014 - 2024 (USD Million) • Rapid acting • Long acting • Premix analogs

Segmentation by region, 2014 - 2024 (USD Million) • North America     • U.S. • Europe     • UK • Asia Pacific     • China     • India • Rest of the world

Key players analyzed • ADOCIA • Biocon • Bioton • Eli Lilly and Company • Novo Nordisk • Sanofi • Wockhardt

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

[healthcare-reports]

Biosimilars Market Analysis, Growth Rate and Forecasts, 2014 to 2024

The global Biosimilars Market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost-effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper than their counterpart biologics. Furthermore, the patent expiry of the blockbuster drugs is anticipated to provide a lucrative opportunity for the growth of biosimilars. For instance, a patent for Bevacizumab, sold under the trade name Avastin is expiring in 2019.

Moreover, increasing government initiatives, speedy drug approvals and reimbursement policies are expected to boost the market for the biosimilars in the study period. Also, market giants are adopting merger & acquisition strategies to increase their product portfolio. For instance, in 2015, Pfizer, Inc. acquired Hospira, a key player in biosimilars market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market

In 2016, oncology was the largest segment, accounting for 32% market share. Increasing prevalence of cancer across the globe is the key factor driving the growth of the market over the forecast period. For instance, according to the American Cancer Society, an estimated 1.6 lakh people suffered from cancer in 2016. Also, increasing government initiatives to provide cost effective treatment to cure deadly diseases will boost the penetration of biosimilar in developing countries which in turn will increase the market for biosimilar over the forecast period. For instance, WHO launched a pilot program for prequalifying biosimilar drug, making some of the most expensive treatments for cancer more widely available in developing countries. Under this initiative, WHO has focused on two essential drug rituximab (principally used for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab (for the treatment of breast cancer).

In terms of region, Europe dominates the market for biosimilars followed by North America. The dominance of Europe is due speedy approval of the drug by European regulatory bodies. Furthermore, improving healthcare infrastructure and ageing population is expected to drive the market over the forecast period. However, Asia Pacific is projected to be the fastest growing region owing to the increasing disposable income of middle-class families, growing medical tourism and improving healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical giants is expected to boost the market in the projected period.

Hexa Research has segmented the global biosimilars market based on indication and region:

Segmentation by indication, 2014 - 2024 (USD Million)

• Blood Disorders

• Oncology

• Chronic & Autoimmune Diseases

• Others

Segmentation by region, 2014 - 2024 (USD Million)

• North America

   • U.S.

• Europe

   • Germany

• Asia Pacific

   • China

   • India

   • Japan

• Rest of the world

Key players analyzed:

• Dr. Reddy’s Laboratories Ltd

• Mylan

• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

• Pfizer Inc.

• Sandoz International GmbH

• Teva Pharmaceuticals Industries Ltd.

• Amgen Inc.

• STADA Arzneimittel AG

• Biocon

• F. Hoffmann-La Roche Ltd.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

[healthcare-reports]

eClinical Solutions Market Overview and Future Outlook, 2016 to 2024

The Global eClinical Solutions Market is anticipated to exceed USD 13 billion by 2024. The major growth driving factors include a rise in the R&D activities by various pharma and biopharma companies, growing application of software solutions in medical trials, rising government funding for promoting clinical research programs, increasing consumer base, and so on. In addition to this, rising outsourcing of medical trials to Contract Research Organization (CROs), growing medical research programs in various Asian countries along with the development of low-cost modules are also projected to boost the market growth.

However, high implementation prices, the lack of skilled labor & awareness about clinical data sciences software are likely to hinder the growth of the market in the near future. The global market is divided into products and regions.

Browse Details of Report @ https://www.hexaresearch.com/research-report/eclinical-solutions-market

The products sector includes Electronic Data Capture (EDC), Electronic Clinical Outcome Assessment (ECOA), Clinical Data Management Systems (CDMS), Randomization and Trial Supply Management (RTSM), Safety Solutions, Clinical Data Integration Platforms, Clinical Trial Management Systems (CTMS), and Electronic Trial Master File (e-TMF). The ECOA sector is projected to experience the maximum growth rate over the forecast period (from 2016 to 2024), while the CDMS and EDC sectors are anticipated to dominate the market through the year 2016.

Regionally, the global eClinical solutions market is segregated as Latin America, North America, Asia-Pacific, Europe, and the Middle East & Africa. As of 2016, the North American market is expected to dominate the global market occupying the largest industry share. The major factor for this growth is the growing number of ongoing medical trials in the region. Some other factors include the rising government support for clinical trials, extensive Research & Development activities resulting in the production and launch of innovative products, and the increasing occurrences of lifestyle diseases. The APAC region is also likely to witness a rapid growth over the next few years. The rising participation of developing countries in the clinical trials is said to augment the market growth during the estimated years.

The key companies operating in the global eClinical solutions market are Parexel International Corp.; ERT inc.; Oracle Corp.; BioClinica; DataTrak International Inc.; Medidata Solution Inc.; Merge Health Inc.; CRF Health Inc.; OmniComm Systems Inc.; and eClinical Solutions LLC.

Related Reports:

Teeth Whitening Products Market - Recommendations from dentist and approvals from the dental associations encourages consumers to utilize lightening products and is anticipated to boost the market over the coming few years.

mHealth Market - Smartphone penetration with 3G and 4G networks has multiplied owing to growing urbanization and purchasing power, which is expected to drive mHealth market growth. 

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com/

[healthcare-reports]

Guidewires Market Overview and Forecast Report, 2016 to 2024

Guidewires are flexible tubes used to guide a catheter to a diseased artery in the heart. They are used for the diagnosis of cardiovascular diseases. It will face huge demand due to the recent trend of minimally invasive procedures. Benefits of these procedures such as fast recovery, reduced hospital stay, and a painless surgical experience will favor the Guidewires Market.

The growing geriatric population and presence of prevalent coronary diseases are factors that can result in increased demand. The guidewires market is projected to grow at a rapid rate from 2016 to 2024 (forecast phase). Reservations by reimbursement companies will hamper the market growth.

Coronary, peripheral, neurovascular, and urology guidewires are the 4 products currently offered in the market. All these products will be of prominent use in the medical sector in the years ahead. In 2013, Terumo Corporation dominated the peripheral guidewires market on account of its expansive product portfolio. Additionally, prominent players of neurovascular guidewires include ASAHI INTECC and Codman Neurovascular.

Browse Details of Report @ https://www.hexaresearch.com/research-report/guidewires-industry

Regions include North America, Latin America, Asia Pacific, Europe, and Middle East & Africa (MEA). North America will lead the guidewires market over the next eight years. This can be attributed to the advanced health infrastructure and cardiovascular and neurovascular diseases in the region. Presence of large manufacturers and their respective specialty products will also favor the regional market growth. Asia Pacific will be the fastest growing market, owing its growth to the economies of China and India.

Research and development play a key role pertaining to the growth of the global market. The companies involved have tried to create cost-effective products to prevent any product recalls. Tip shape retention and flexibility are the prime requirements of health practitioners while handling guidewires. Well-known players in the market are ASAHI INTECC, Terumo Corporation, Boston Scientific Corporation, and Abbott Laboratories.

New product launches and collaborations with healthcare practitioners are a common strategy followed by these players. For instance, Boston Scientific has launched Safari preshaped TAVI guidewires, Fathom Steerable Guidewires, choice Floppy guidewires, Journey Guidewire, and Kinetix Guidewires. The Fathom series has advanced micro fabrication technology which can be used to treat tortuous vasculature. Safari series can retain its shape and comes in three sizes.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - https://www.hexaresearch.com/

[healthcare-reports]

China Bioprocess Instruments Market Analysis and Forecast Report, 2014 to 2024

The China Bioprocess Instruments Market is expected to reach USD 3.06 billion by 2024 owing to the improving economy, rising aging population and increasing prevalence of chronic diseases. Moreover, increasing demand for single-use instruments in disposable applications is anticipated to augment the growth over the projected period.

China was the second largest pharmaceutical market in the world, expected to grow USD 173 billion by 2024, growing at a CAGR of 9.1% owing to the requirement of medication & drugs to cure deadly diseases. Huge investment in biotechnology will primarily drive the growth of the market, as pharma companies deal in innovations for developing medicines and drugs in line with the increasing prevalence of diseases.

Browse Details of Report @ https://www.hexaresearch.com/research-report/china-bioprocess-instruments-market

With the patents of numerous biopharmaceutical products expiring by 2016, the market is anticipated to provide a lucrative opportunity for contract manufacturers operating in the region. Approval of the trail plan for new drug marketing authorization holder (MAH) in 2016 to produce, conduct clinical trials, and market the products is expected to provide an impetus to the growth of the industry over the next few years.

Increasing demand for bioprocess instruments in the pharmaceutical, research & development, industrial and medical laboratories coupled with the increasing number of these facilities is expected to result in the growth of the market. Change in lifestyle & food consuming habits, and growing levels of air & water pollution have led to increasing occurrence of disease including obesity which has resulted in a rising number of patients diagnosed with cancer, heart disease, diabetes and other chronic conditions. Thus, the healthcare sector is anticipated to create demand for treatment and laboratory services, which will result in the growth of bioprocess instruments market over the forecast period.

Stringent regulatory policies and the high cost of instruments are likely to restrain the bioprocess instruments market in China. The government has been focusing on reducing the fragmentation in the industry by consolidating manufacturers that lack standards in production with larger companies. This move will help in preventing the quality risks and sub-par manufacturers entering the market. Shortage of skilled labor is another challenge in the growth of bioprocessing industry.

Koninklijke Philips N.V., Thermo Fisher Scientific Inc. and Becton, Dickinson and Company were the top three companies in the market in China in 2016. Companies are extensively investing in R&D for innovation and new product development. In addition, companies are adopting the strategy of merger and acquisition to expand their product portfolio.

Hexa Research has segmented the China bioprocess instruments market based on type:

Segmentation by type, 2014 - 2024 (USD Million)

• Cell Expansion

• Flow Cytometry

• Biologics Safety Testing

• Cell Line Development

• Tangential Flow Filtration

• Cell Counters

• Virus Filtration

• Cell Culture

• Pyrogen Testing

• Single-Use Bioprocessing

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

[healthcare-reports]

Neurostimulation Devices Market Analysis and Future Outlook, 2012 to 2020

A recent study by Hexa Research revealed that limited range of treatment choices relating to medical conditions like epilepsy, Alzheimer’s disease, Parkinson’s disease, migraine headaches, etc. is one of the key drivers of the global Neurostimulation Devices Market. An upcoming application area is the use of neurostimulation devices for therapeutic purposes, commonly referred to as neuromodulation. The neurostimulation devices market is benefitting from technological advancements like the transdermal neuromodulation technology by Neurowave Medical Technologies and MRI safety-enabled devices by Medtronics, Inc.

Rising elderly populace - a high risk demographic for Parkinson’s and Alzheimer’s, is also driving market growth. Accelerated demand for neurostimulation devices in the future years is expected to result from untapped market opportunities in emerging economies of Asia as well as Latin America and the growing number of externally funded clinical programs for development of new products.

Browse Details of Report @ https://www.hexaresearch.com/research-report/neurostimulation-devices-industry/

Hexa Research identifies spinal cord stimulation devices, vagus nerve stimulation devices, gastric electric stimulation devices, deep brain stimulation devices, and sacral nerve stimulation devices to be the key product segments in the neurostimulation devices market. Spinal cord stimulation devices, with a contribution of more than half to the total revenues, were the dominant product segment in 2012.

Pain management proved to be the largest application of neurostimulation devices in 2012 and contributed more than 65% to the total demand that year. This was chiefly due to high incidence of conditions characterized by chronic pain and notable therapeutic effects offered by neurostimulation devices.

While North America contributed around 64% to the total revenues in 2012, Asia Pacific is likely to grow the fastest in future. Fast-developing economies like India and China will result in the Asia Pacific neurostimulation devices market growing at CAGR higher than 16% from 2013 to 2020.

Hexa Research observes that the neurostimulation devices industry exhibits outsourcing of expensive manufacturing activities. This enables industry participants to achieve cost efficiency and better profitability. Key industry players include Boston Scientific Corporation, Cyberonics, Medtronic Inc., and St. Jude Medical.

Browse Related Category Market Reports @  https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

[healthcare-reports]

Sevoflurane, Isoflurane and Desflurane Market Research Report, 2022

Overview

The Sevoflurane, Isoflurane and Desflurane Market is expected to reach USD 1.5 billion by 2022 in comparison to USD 1.2 billion in 2014. These three chemicals are inhalation agents and have been used by anesthesiologists, nurse anesthetists, and anesthesiology assistants on a consistent basis. They are very strong and cost less, with minimum damage to the ozone layer.

Market Drivers

One of the primary factors, triggering expansion in the sevoflurane, isoflurane and desflurane market includes cardiovascular and respiratory diseases affecting the geriatric population. Rising cancer, orthopedic, spinal and gastro-intestinal cases have also furthered the market. Cataract surgery is a major contributor to the global market and will need a higher production of these chemicals.

Growing accidents and emergency cases also add income to the inhalation anesthesia market. Universal insurance coverage as well as constant improvements in medical infrastructure also ensure the development of the sevoflurane, isoflurane and desflurane market. These agents are administered to patients prior surgery, making the induction of general anesthesia much simpler.

A major factor hindering the market is the quantity of CO2 released in the environment, leading to global warming. Actually, only about 5 percent of the gases are consumed by patients. The rest are released into the atmosphere and make it unhealthy. The most practical solution for this problem is the anesthetic recycling of products used during the administration of general anesthesia.

Browse Details of Report @ http://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry/

Products Overview

Sevoflurane:

Sevoflurane is one of the most commonly used volatile anesthetic agents. It is administered to babies and children. Sevoflurane is ideal for patients with asthma or sensitive air passages. But its side-effects include delirium and agitation. It can be given quickly without the use of intravenous instruments.

Sevoflurane would capture over 70% of the worldwide sevoflurane, isoflurane and desflurane market by 2022. The agent is expected to exceed USD 1 billion by the same year. It’s widely utilized for being low-priced and possessing therapeutic benefits.

Isoflurane:

Isoflurane is a halogen ether utilized frequently by veterinarians. It is administered intravenously, relaxes the muscles and reduces pain. Isoflurane has also been used for inducing sleepiness for long durations during surgery. It is expected to register a CAGR of about 10% by 2022.

Desflurane:

Desflurane is a halogen ether used in general anesthesia. Its effectiveness is one-fifth of isoflurane. Desflurane cannot be administered orally and requires an electrically heated dispenser to distribute the vapor. It is mostly administered to bariatric patients and in cases of surgeries lasting for short durations.

Regional Overview:

The United States has a large geriatric population. This has led the region of North America to occupy the biggest share in the worldwide inhalation anesthesia market in 2014. Surgical ambulatory and inpatient procedures are the driving factors of North America.

Asia Pacific will experience the fastest growth by 2022. This is owing to the rise of chronic diseases and need for better health infrastructure in the region. Medical tourism combined with insurance coverage will play a huge role in sustaining the growth of the sevoflurane, isoflurane and desflurane market.

Key Players:

The market is currently dominated by AbbVie and Baxter International. However, it can   expect strong competition from manufacturers like Lunan Pharmaceutical Group and Piramal Enterprises.

Piramal Enterprises currently has isoflurane and sevoflurane production underway. It will manufacture generic desflurane by 2016. AbbVie has sevoflurane and isoflurane under production. Baxter International is the only one that manufactures all the three products.

Anesthesia has some unhealthy effects. The recycling companies of Deltasorb Technologies and Anesthetic Gas Reclamation reprocess anesthesia containers and gases from hospital vents. Rising investments by the aforementioned players would also accelerate the sales of the sevoflurane, isoflurane and desflurane market.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

[healthcare-reports]

Molecular Diagnostics Market Analysis, Growth and Forecasts to 2024

The Molecular Diagnostics Market was valued at over USD 6.40 billion in 2015. It is likely to grow at a CAGR of around 9% during the forecast period (2016-2024).

Increasing prevalence of infectious diseases, cancer, genetic disorders, and other contagious disease are likely to drive the molecular diagnostics industry. Hospital acquired infections and other communicable infections are expected to boost market growth in the coming eight years. Moreover, prenatal genetic testing is also expected to increase the adoption of this diagnostics.

Unhealthy lifestyle can further contribute to large number of people getting afflicted with chronic ailments like cardiovascular disorders and diabetes. This with further propel market growth in the coming years. Molecular diagnostics market is divided into products, technologies, applications, test location, and regions.

Browse Details of Report @ https://www.hexaresearch.com/research-report/molecular-diagnostics-industry

On the basis of products, the market is split into instruments, reagents, and others. Reagents segment held the largest share in 2015 with revenues exceeding USD 3.5 billion. It is expected to grow at a CAGR surpasing 12%. Instruments segment is expected to show a significant growth in the coming years.

Technologies consist of polymerase chain reaction (PCR), in-situ hybridization, chips and microarrays, mass spectrometery, DNA sequencing, transportation mediated amplification, and others. PCR held the largest market share of over USD 2.5 billion in 2015. Growth of this segment can be attributed to its high incorporation among the researchers and healthcare professionals. DNA sequencing is likely to show a growth of about 16% CAGR in the coming years.

Applications encompass oncology, pharmacogenomics, infectious diseases, genetic testing, neurological diseases, cardiovascular diseases, and others. Infectious diseases segment was the largest application holding market share exceeding 45% in 2015.

Oncology segment is anticipated to show a CAGR of about 13% till 2024. Rising awareness among people regarding early cancer diagnosis is the key aspect propelling market growth of the segment.

Test location comprises of point of care (PoC), self test or over the counter (OTC), and central laboratories. Central laboratories dominated the market with over 60% shares in 2015. The growth of the central laboratories can be attributed to their large prominence in underdeveloped countries, rising awareness about early detection of diseases, and high procedure volumes.

The PoC is expected to project a lucrative growth with a CAGR of more than 14%. The growth of this segment can be attributed to the increasing demand of bedside patient monitoring and innovative technological devices.

Regions are fragmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA). America dominated the market with over 40% revenue share. Asia Pacific is likely to exhibit a growth of around 12%CAGR in the coming years.

The key global players of the molecular diagnostics market include Siemens Healthcare GmbH, Novartis AG (Grifols), F. Hoffmann-La Roche Limited, and Johnson & Johnson.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/biotechnology-industry  

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/